But assuming 5 or more competitors early in the sales cycle, is very pessimistic, is it not?
Apart from that, surely the value in Acrux is more in the broader pipeline, and going forward in the ability to run a sustained R&D program that feeds a commercial pipeline?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.002(11.1%) |
Mkt cap ! $6.548M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.0¢ | 1.6¢ | $39.34K | 2.216M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 971151 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 565000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| ACR (ASX) Chart |